Ventura Biomed Investors

Ventura Biomed Investors is a venture capital firm based in Munich, Germany, dedicated to shaping the future of biomedicine by investing in early-stage life science companies. The firm focuses on pioneering technologies and innovative therapies within the European market. They typically invest between EUR 1 and 5 million per company, often in consortia with other funds. To broaden their impact, Ventura Biomed Investors also leverages its investment platform, Ventura Ace, which includes a network of selected private investors.

The firm was founded by Dr. Andreas Jenne and Dr. Kurt Rudolf Schwarz, both serial entrepreneurs with extensive experience in the biotech and pharmaceutical industries. Dr. Jenne has a strong background in launching and managing biotech companies, including Kinaxo and NEO New Oncology, both of which were successfully acquired. Dr. Schwarz is an active investor and business angel with affiliations including Merck & Co., Harvard Medical School, and Massachusetts General Hospital, and previously served on the supervisory board of Schwarz Pharma.

Ventura Biomed Investors boasts a diverse portfolio of innovative life science companies. Notable investments include Kupando, which develops TLR 4/7 agonists for oncology and infectious diseases; NEOSPHERE Biotechnologies, a proteomics company focused on discovering therapeutic degrader targets; IRUBIS, offering real-time bioprocess monitoring instruments; Abalos Therapeutics, developing a novel virus-based anti-cancer therapy; and Navignostics, providing spatial single-cell proteomic analysis for personalized cancer treatment. The firm's investments span areas such as drug discovery, diagnostics, and bioprocess technology.

The leadership team's deep industry knowledge and broad investor and business network are crucial to their strategy. They actively support the long-term development of their portfolio companies, providing not just capital but also strategic guidance and access to key industry connections. This hands-on approach aims to accelerate medical breakthroughs and address unmet patient needs.